Lipoprotein(A) Levels and Diabetes Control

Wolffenbuttel, Bruce H. R.; Sels, J. P. J. E.; Heesen, B J; Menheere, P. P. C. A.; Kruseman, A. C. Nieuwenhuijzen

doi:10.2337/diacare.15.7.941

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have found elevated levels of Lp(a) in poorly controlled diabetics, whether insulin‐dependent (IDD) or non‐insulin‐dependent (NIDD) 115 . Reductions in Lp(a) levels following improvement of glycaemic control have been observed in subjects with IDD, 116–118 but not in those with NIDD 119–121 . Another study found no difference between Lp(a) concentrations in diabetics (either IDD or NIDD) and controls, and the authors concluded that there was no evidence from their study that Lp(a) levels contributed to the increased risk of atherosclerosis in diabetics 122 …”

Section: Lp(α) and Diseasementioning

confidence: 98%

LIPOPROTEIN(α) IN HEALTH AND DISEASE

Byrne

Wild

1994

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY Elevated plasma levels of Lp(a) do seem to influence the progression of atherosclerosis. Evidence is emerging that certain apo(a) isoforms may be more atherogenic than others, and in transgenic mice free apo(a) has been shown to be associated with accelerated atherosclerosis. Currently it is not known whether treating elevated Lp(a) levels will reduce progression of atherosclerosis and, as therapeutic options are limited, mass screening of Lp(a) levels in populations is not indicated. The presence of raised Lp(a) levels, however, warrants aggressive treatment to reduce other cardiovascular risk factors. Continuing research to investigate the relationship of the apo(a) gene to other genes, including the plasminogen gene and apo(a)‐related genes, will add further information pertaining to the evolution, function, regulation and clinical implications of Lp(a).

show abstract